Metastatic nonseminomatous germ cell tumors of the testis: Results of elective and salvage surgery for patients with residual retroperitoneal masses

Cancer

Volumn 94, Issue 6, 2002, Pages 1668-1676

  Hendry, William F ^a   Norman, Andrew R ^a   Dearnaley, David P ^a,b   Fisher, Cyril ^a   Nicholls, Judy ^a   Huddart, Robert A ^a   Horwich, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Histology; Neoplasm; Para aortic lymphadenectomy; Residual; Survival; Testicular neoplasms; Testis

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; ELECTIVE SURGERY; FIBROSIS; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TERATOMA; METASTASIS; MINIMAL RESIDUAL DISEASE; MORBIDITY; NECROSIS; NON SEMINOMATOUS GERMINOMA; OUTCOMES RESEARCH; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; RETROPERITONEAL TUMOR; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURGICAL MORTALITY; SURVIVAL RATE; TESTIS TUMOR; TUMOR RECURRENCE; UNDIFFERENTIATED CARCINOMA;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GERMINOMA; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; MORBIDITY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROGNOSIS; RETROPERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURGICAL PROCEDURES, ELECTIVE; TESTICULAR NEOPLASMS;

EID: 0037086467     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10440     Document Type: Article

References (56)

1. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: Long-term follow-up
2. Post-chemotherapy surgery in advanced non-seminoma germ cell tumours: The significance of histology with particular reference to differentiated (mature) teratoma
3. Elective delayed excision of bulky para-aortic lymph node metastases in advanced non-seminoma germ cell tumours of testis
4. The detection and localisation of abdominal lymph node metastases from testicular teratomas
5. The role of surgery in the combined management of metastases from malignant teratomas of testis
6. The role of surgery in the combined management of metastases from testicular teratomas of testis
7. Para-aortic lymphadectomy after chemotherapy for testicular tumour
8. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: Prognostic value and therapeutic benefit
9. Decision making in abdominal surgery following chemotherapy for testicular cancer
10. Non-seminomatous germ cell testicular tumours - Masses after chemotherapy
11. The role of radiotherapy after chemotherapy in the management of persistent paraaortic nodal disease in non-seminomatous germ cell tumours
12. Improved chemotherapy in disseminated testicular cancer
13. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP)
14. Intensive induction chemotherapy for poor risk tumours
15. Salvage therapy and autologous bone marrow transplantation
16. Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT)
17. Salvage therapy of germ cell tumours
18. Ejaculatory dysfunction after retroperitoneal lymphadenectomy
19. Non-parametric estimation from incomplete observations
20. Asymptotically efficient invariant procedures
21. The growing teratoma syndrome
22. The variable transformation in metastases from testicular germ cell tumours: The need for selective biopsy
23. Testicular relapse after chemotherapy for malignant teratoma
24. Late relapse in testicular cancer after chemotherapy
25. Treatment of retroperitoneal residual tumor after PVB chemotherapy of non-seminomatous testicular tumours
26. Late recurrence of mature teratoma in nonseminomatous testicular tumour after PVB chemotherapy and surgery
27. Late relapse in testicular cancer from a residual tumour
28. Retroperitoneal malignancies several years after initial treatment of germ cell cancer of the testis
29. Clinical and radiological correlation of retroperitoneal metastasis from nonseminomatous testicular cancer treated with chemotherapy
30. Teratoma following chemotherapy for non-seminomatous germ-cell tumor: A clinicopathologic correlation
31. The development of non-germ cell maligancies within germ cell tumours. A clinicopathologic study of 11 cases
32. Sarcoma arising in a residual testicular teratoma after cytoreductive chemotherapy
33. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer
34. Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer: A decision analysis
35. Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT)
36. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: Is a modified dissection and resection of residual masses sufficient?
37. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer
38. Hepatic resection of metastatic testicular carcinoma: A further update
39. Modified neck dissection for metastatic nonseminomatous testicular carcinoma
40. Pulmonary metastasectomy for testicular germ cell tumors: A 28-year experience
41. Combined post-chemotherapy retroperitoneal lymph node dissection and resection of chest tumor under the same anesthetic is appropriate based on morbidity and tumor pathology
42. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: A plea for an aggressive surgical approach
43. The role of surgery following chemotherapy in Stage III germ cell neoplasms
44. Significance of salvage lymphadenectomy in the therapeutic concept of advanced non seminomatous germ cell tumors
45. Excision of residual masses after platinum based chemotherapy for nonseminomatous germ cell turnouts
46. Radical retroperitoneal node dissection after chemotherapy for testicular tumours
47. The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours
48. Patient selection for retroperitoneal lymph node dissection after chemotherapy for non seminomatous germ cell tumours
49. Cytoreductive surgery in disseminated nonseminomatous germ cell tumours
50. Management of retroperitoneal recurrences: Seminoma and nonseminoma
51. Integration of surgery and systemic therapy: Results and principles of integration
52. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers
53. Complications of retroperitoneal lymph node dissection
54. Complications of lymph node dissection
55. Complications of thoraco-abdominal retroperitoneal lymph node dissection